ClinicalTrials.gg
Active, not recruitingNCT07290868Diactive-1v2Updated Oct 9, 2026

Diactive-1: Scaled-up Personalized mHealth Program for Youth With Type 1 Diabetes

An interventional study of Diactive-1 in Type 1 Diabetes (T1D), sponsored by Fundacion Miguel Servet. Active, not recruiting at 1 site in Spain. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Fundacion Miguel Servet · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
55th of 113
158 · median 153
Started
2026
with 10 others
No phase
55 of 150
12 open now
Primary completion
2026-12
later than 12 of 29 live
Registered
140th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 55th largest by planned enrollment of the 113 interventional ones that give a count, is one of 11 that started in 2026, is one of 55 with no phase, reaches primary completion later than 12 of the 29 other live ones, and was the 140th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

The Diactive-1 project aims to establish the Diactive-1 mobile application as a clinical tool for managing type 1 diabetes in children and adolescents in several hospitals from Spain. The successful implementation of the app in new healthcare centers nationwide represents a key step toward the development of a comprehensive and scalable program. This approach seeks not only to optimize current patient care but also to democratize access to an innovative, evidence-based intervention that supports daily diabetes management.

In this new phase, the project will integrate the application into routine clinical care for patients with type 1 diabetes through the use of a simple handgrip strength measurement. A dedicated web platform (www.diactive.es) is being developed to allow clinicians to enter basic patient data, including handgrip strength, sex, and email address. Based on this information, the system will automatically generate a personalized download link for the Diactive-1 app, accompanied by tailored guidance and an initial fitness level classification (low, medium, or high) according to European reference values.

This process will define each user's baseline fitness level and facilitate the use of Diactive-1 as an integrated and individualized disease management tool. The ultimate goal is to strengthen clinical decision-making, improve patient engagement, and extend the benefits of digital health to a broader pediatric population living with type 1 diabetes.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • mHealth
  • Resistance training
  • Education
  • Handgrip strength
04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 1 Diabetes Mellitus (T1DM) for 6 months or longer (requiring >0.5 U/kg/day of insulin and having >6%, i.e., not in the "honeymoon phase").
  • Receiving multiple daily injection (MDI) therapy or insulin pump therapy (CSII).
  • Signed authorizing legal participation in the research project (child/adolescent and parent(s)/legal guardian).
  • Availability to participate in the study using an m-Health application (Diactive-1) designed for the programming of muscle-bone strengthening physical exercise.
  • Understanding of Spanish.

Exclusion criteria

Exclusion Criteria:

  • Comorbidities that limit the ability to engage in physical activity.
  • Lack of internet access when using the application, whether due to Wi-Fi, mobile data, or international roaming issues.
  • Absence of a mobile phone or tablet with an Android or iOS (Apple) operating system, or no family member willing to lend a device for each session using the application for study-related purposes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
158 participants (estimated)

Study arms

  • Experimental
    Diactive-1

    The intervention in the experimental group will center around the use of a mobile application (i.e., device), namely the Diactive-1 app.

    Device: Diactive-1

  • No intervention
    Waiting-list control group

    This arm will not complete an intervention. Participants will be instructed to continue to follow their normal daily diabetes care plan (i.e., standard care). This group will be granted access to the app following the intervention.

Interventions

  • DeviceDiactive-1

    Participants will engage in a 12-week resistance exercise program with the goal of maintaining at least 3 sessions per week, with 3-6 exercises per session (≈13-33 minutes). Participants will be able to choose among three training formats, traditional resistance training, Tabata/high-intensity intervals, or circuit training, and may perform the sessions individually or in pairs, depending on preference and feasibility at the center. The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper body, lower body, and core, using primarily the participants' own body weight. The load and intensity of the exercise will be adjusted according to the number of repetitions and the difficulty/progression of the selected exercises. A mobile application (Diactive-1) will be used to deliver, monitor, and record the sessions.

06

What researchers measure

Primary outcomes

  1. Change in handgrip strength

    Handgrip strength measured in kilograms using the Takei III Smedley Type Digital Dynamometer

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in daily insulin dose requirement

    The daily insulin dose requirements will be measured in units per kilogram of body weight. Assessment will rely on participant-reported data from insulin pumps or injection logs, gathered for 7 days prior to the intervention and after the intervention.

    Time frame: Baseline and 12 weeks

  2. Change in glycated hemoglobin

    Glycated hemoglobin (measured in percent)

    Time frame: Baseline and 12 weeks

  3. Number of participants with good glycemic control

    Number of participants with a glycated hemoglobin level lower than 7%

    Time frame: Baseline and 12 weeks

  4. Change in time in range

    The percentage of time a person spends with their blood glucose levels in the target range (70-180 mg/dL or 3.9-10 mmol/L) (measured in percent)

    Time frame: Baseline and 12 weeks

  5. Change in time below range

    The percentage of time a person spends with their blood glucose levels below the target range (\<70 mg/dL or \<3.9 mmol/L, i.e., hypoglycemia) (measured in percent)

    Time frame: Baseline and 12 weeks

  6. Change in time above range

    The percentage of time a person spends with their blood glucose levels above the target range (\>180 mg/dL or 10 mmol/L, i.e., hyperglycemia) (measured in percent).

    Time frame: Baseline and 12 weeks

  7. Change in glycemic variability

    Glycemic variability measures the fluctuation in blood glucose levels over time, expressed as a percentage. Lower glycemic variability indicates more stable levels, while higher glycemic variability suggests greater fluctuations.

    Time frame: Baseline and 12 weeks

  8. Change in compliance with 24-hour movement behaviors

    Physical activity at different intensities (average min/day), sedentary time (average min/day) and sleep (average min/day) will be measured using self-reported questionnaires.

    Time frame: Baseline and 12 weeks

  9. Change in self-reported physical activity

    Aerobic and muscle-strengthening activities will be assessed using two separate ad hoc questions. Participants will have response options ranging from 0 to 7 days per week, with increments of 1 day.

    Time frame: Baseline and 12 weeks

  10. Change in self-reported physical fitness

    The International Fitness Scale (IFIS) will be used to assess self-reported physical fitness. This scale includes five elements that will employ a 5-point Likert scale to inquire about children's overall perception of their physical fitness, as well as their perception of their cardiorespiratory fitness, muscular fitness, speed-agility, and flexibility compared to their peers. The Likert scale will provide choices ranging from 'very poor' to 'poor,' 'average,' 'good,' and 'very good' physical fitness.

    Time frame: Baseline and 12 weeks

  11. Change in sleep duration

    Sleep duration will be determined by recording the number of hours slept each day

    Time frame: Baseline and 12 weeks

  12. Change in physical literacy

    Physical literacy will be assessed using the Spanish Perceived Physical Literacy Instrument (S-PPLI), a 9-item questionnaire that evaluates three dimensions: knowledge and understanding; self-expression and communication; and sense of self and self-confidence

    Time frame: Baseline and 12 weeks

  13. Change in physical activity barriers

    We will use the Spanish adaptation of the Physical Activity Barriers Scale for pediatric type 1 diabetes (PABS-1), a validated instrument for assessing perceived barriers to physical activity in children and adolescents with type 1 diabetes

    Time frame: Baseline and 12 weeks

  14. Adherence to the Mediterranean Diet

    For assessing adherence to the Mediterranean Diet, the KIDMED index will be employed. This index provides a score on a scale of 0 to 12, with higher scores indicating stronger adherence.

    Time frame: Baseline and 12 weeks

  15. Change in disordered eating

    Disordered eating will be screened using the mSCOFF questionnaire. This questionnaire consists of six straightforward yes/no questions. A positive response to two or more of these questions suggests a potential eating disorder, often requiring further evaluation.

    Time frame: Baseline and 12 weeks

  16. Change in subjective well-being

    Subjective well-being will be assessed using the CUBE questionnaire, which comprises five items that evaluate different aspects of life satisfaction and emotional states.

    Time frame: Baseline and 12 weeks

  17. Change in Health-Related Quality of Life

    Health-Related Quality of Life will be evaluated using the Screening for and Promotion of Health-Related Quality of Life in Children and Adolescents (KIDSCREEN-10).

    Time frame: Baseline and 12 weeks

  18. Change in Health-Related Quality of Life in the context of a chronic illness

    Health-Related Quality of Life in the context of a chronic illness will be evaluated using the Spanish version of the 'Questionnaire for Young People with Diabetes' (DISABKIDS).

    Time frame: Baseline 12 weeks

  19. Change in microalbuminuria

    Microalbuminuria will be evaluated as an indicator of early kidney involvement. A first-morning urine sample will be collected, and the albumin-to-creatinine ratio (ACR) will be determined using standardized laboratory procedures. Values will be expressed in mg/g. Microalbuminuria will be defined as an ACR between 30 and 300 mg/g, according to international diabetes guidelines.

    Time frame: Baseline and 12 weeks

  20. Change in retinal findings

    Retinal imaging will be performed to assess early signs of diabetic retinopathy. Images of both eyes will be captured following standard ophthalmologic protocols and evaluated by trained specialists. Findings will be categorized as no retinopathy, mild, moderate, or severe diabetic retinopathy, based on international classification criteria.

    Time frame: Baseline and 12 weeks

  21. Change in body mass index

    Weight and height will be combined to report body mass index in kg/m\^2

    Time frame: Baseline and 12 weeks

  22. App usability: user

    The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS).

    Time frame: 12 weeks

  23. App usability: expert evaluation

    We will employ the Spanish adaptation of the Mobile Application Rating Scale (MARS), a standardized instrument for expert appraisal of mHealth applications.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Sanchez-Arlegui A, Munoz-Pardeza J, Hormazabal-Aguayo I, Abio-Abero S, Bertholt-Zuber ML, Alonso-Rubio P, Burillo-Sanchez E, Chueca-Guindulain MJ, Cifuentes-Zamalloa C, Congost-Marin S, Diez-Lopez I, Ferrer-Lozano M, Garcia-Navas P, Gonzalez-Garcia LG, Huidobro-Fernandez B, Lalaguna-Mallada P, Llorente-Cereza MT, Maeso-Mendez S, Riano-Galan I, Ruiz-Del Campo M, Salcedo Fresneda O, Vara-Callau M, Vela-Desojo A, Ezzatvar Y, Garcia-Hermoso A. Scale-up of the Diactive-1 mHealth program integrating tailored resistance training as an educational strategy for self-management in children and adolescents with type 1 diabetes: protocol for an 11-hospital multicenter randomized controlled trial. Front Endocrinol (Lausanne). 2026 Aug 14;17:1913568. doi: 10.3389/fendo.2026.1913568. eCollection 2026. PubMed 42666156 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 11 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 18, 2025
StartActual
Jan 28, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42666156 ↗
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42666156 ↗
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07290868
Lead sponsor
Fundacion Miguel Servet
Collaborators
Universidad Pública de Navarra, University of Valencia, Fundación Instituto de Investigación Sanitaria de Navarra
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jan 28, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion